A5041835601- Pancreatic and Hepatic Oncology Research
- Epigenetics and DNA Methylation
- MicroRNA in disease regulation
- Clostridium difficile and Clostridium perfringens research
- Cancer, Hypoxia, and Metabolism
- Gut microbiota and health
- Pregnancy and preeclampsia studies
- Cancer Genomics and Diagnostics
- Circular RNAs in diseases
- PARP inhibition in cancer therapy
- Diet and metabolism studies
- Diet, Metabolism, and Disease
- COVID-19 diagnosis using AI
- Reproductive System and Pregnancy
- Melanoma and MAPK Pathways
- Adenosine and Purinergic Signaling
- Neuroblastoma Research and Treatments
- Cancer therapeutics and mechanisms
- Prostate Cancer Treatment and Research
- RNA modifications and cancer
- Viral-associated cancers and disorders
- SARS-CoV-2 and COVID-19 Research
- Calcium signaling and nucleotide metabolism
- SARS-CoV-2 detection and testing
- Advanced Breast Cancer Therapies
Makerere University
2020-2024
Case Western Reserve University
2024
University School
2024
Case Comprehensive Cancer Center
2024
Abstract Pancreatic ductal adenocarcinoma (PDAC) is associated with a five-year overall survival rate of just 13%, and development chemotherapy resistance nearly universal. PDAC cells overexpress wild-type IDH1 that can enable them to overcome metabolic stress, suggesting it could represent therapeutic target in PDAC. Here, we found anti-IDH1 therapy enhanced the efficacy conventional chemotherapeutics. Chemotherapy treatment induced ROS increased TCA cycle activity cells, along induction...
Abstract Information on microbiota dynamics in pulmonary tuberculosis (TB) Africa is scarce. Here, we sequenced sputa from 120 treatment-naïve TB patients Uganda, and investigated changes of 30 with treatment-response follow-up samples. Overall, HIV-status anti-TB treatment were associated microbial structural abundance changes. The predominant phyla Bacteroidetes , Firmicutes Proteobacteria, Fusobacteria Actinobacteria, accounting for nearly 95% the sputum composition; genera across time...
Pancreatic cancer is the third leading cause of death in United States, and while conventional chemotherapy remains standard treatment, responses are poor. Safe alternative therapeutic strategies urgently needed
<div>Abstract<p>Pancreatic ductal adenocarcinoma (PDAC) is associated with a 5-year overall survival rate of just 13%, and development chemotherapy resistance nearly universal. PDAC cells overexpress wild-type isocitrate dehydrogenase 1 (IDH1) that can enable them to overcome metabolic stress, suggesting it could represent therapeutic target in PDAC. Here, we found anti-IDH1 therapy enhanced the efficacy conventional chemotherapeutics. Chemotherapy treatment induced reactive...
Abstract Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related deaths in the United States. While Poly (ADP-ribose) polymerase (PARP) inhibitors hold promise treating PDAC with Homologous Recombination Deficiency (HRD). However, HRD occurs only 10% cases, leaving 90% intact Proficiency (HRP). Our research highlights key role wild-type isocitrate dehydrogenase 1 (IDH1) maintaining cellular function. We found that inhibiting IDH1 increases DNA damage,...
Abstract Introduction: Pancreatic cancer has the lowest 5-year survival rates among all cancers because of challenges with early detection, its aggressive nature, and resistance to chemotherapy; this makes prevention a promising approach for reducing related mortalities. The disease is predominantly diagnosed in individuals over 60, suggesting that age-related physiological decline impacts onset; therefore, delaying aging hallmarks may delay onset. Nicotinamide dinucleotide (NAD+) precursors...
Abstract Introduction When COVID-19 hit the world in 2019, an enhanced focus on diagnostic testing for SARS-CoV-2 was essential a successful pandemic response. Testing laboratories stretched their capabilities new coronavirus by adopting different test methods. The necessity of having external quality assurance (EQA) mechanisms even more critical due to this rapid expansion. However, there lack experience providing necessary EQA materials, especially locations with constrained resources....
Abstract Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States. While Poly (ADP-ribose) polymerase (PARP) inhibitors show promise for PDAC with Homologous Recombination Deficiency (HRD), this mutation present less than 10% cases. Our research focuses on exploiting vulnerability remaining 90% HR proficient (HRP) tumors. We identified that wild-type isocitrate dehydrogenase 1 (IDH1) plays critical role repair. By inhibiting...
<p>Figure S2</p>
<p>Figure S3</p>
<div>Abstract<p>Pancreatic ductal adenocarcinoma (PDAC) is associated with a 5-year overall survival rate of just 13%, and development chemotherapy resistance nearly universal. PDAC cells overexpress wild-type isocitrate dehydrogenase 1 (IDH1) that can enable them to overcome metabolic stress, suggesting it could represent therapeutic target in PDAC. Here, we found anti-IDH1 therapy enhanced the efficacy conventional chemotherapeutics. Chemotherapy treatment induced reactive...
<p>Dataset1</p>
<p>Figure S2</p>
<p>Dataset1</p>
<p>Dataset2</p>
<p>Dataset2</p>
<p>Figure S4</p>
<p>Figure S4</p>
<p>Figure S5</p>
<p>Supplementary Data</p>
<p>Supplementary Data File</p>
<p>Figure S1</p>
<p>Supplementary Data File</p>
<p>Figure S3</p>